98%
921
2 minutes
20
Introduction: Our aims were to explore the relationship between primary hyperparathyroidism (pHPT) and malignant tumour development, to determine the frequency and the time of occurrence of malignant tumours in patients with pHPT, and to evaluate the characteristics of pHPT in these patients.
Material And Methods: This retrospective cohort study included consecutive individuals who were diagnosed with pHPT aged 18 years or older in a university hospital during a 7-year period. A total of 198 patients with pHPT were reviewed retrospectively. Demographic, clinical, biochemical, radiologic findings, and histopathological diagnosis were collected from the electronic medical records of the hospital system.
Results: The mean age of the study population was 58 ± 13 years and was predominantly female (female/male: 162/36). There were 42 (21.2%) patients with malignant tumours. Five (12%) out of 42 patients had metachronous double malignancies. The most common 2 concurrent malignancies were breast (36.1%) and thyroid (17.0%). Sixty-eight per cent of the malignant tumours occurred before the diagnosis of pHPT. A higher percentage (87.5%) of simultaneous tumours was seen in the thyroid gland. No statistically significant differences were observed between patients with and without malignant tumours in terms of demographic, clinical, biochemical, radiological, and histopathological features. The median follow-up duration was 24 months after parathyroid surgery.
Conclusion: The results of this study revealed that pHPT was associated with various tumour types. The frequency of malignant tumours was 21.2%. Breast and thyroid cancers were the most common 2 cancers coexisting with pHPT. A large percentage of malignant tumours occurred before the diagnosis of pHPT. A higher percentage of simultaneous tumours was seen in the thyroid gland. pHPT patients with and without malignant tumours seemed to have similar characteristics.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5603/EP.a2023.0055 | DOI Listing |
J Appl Clin Med Phys
September 2025
Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia, USA.
Purpose: Real‑time magnetic resonance-guided radiation therapy (MRgRT) integrates MRI with a linear accelerator (Linac) for gating and adaptive radiotherapy, which requires robust image‑quality assurance over a large field of view (FOV). Specialized phantoms capable of accommodating this extensive FOV are therefore essential. This study compares the performance of four commercial MRI phantoms on a 0.
View Article and Find Full Text PDFNutr J
September 2025
Department of Gastroenterology and Hepatology, Hangzhou Red Cross Hospital, 208 Huancheng Dong Road, Hangzhou, 310003, Zhejiang Province, China.
Background: The potential association between dietary inflammatory index (DII) and colorectal cancer (CRC) risk, as well as colorectal adenomas (CRA) risk, has been extensively studied, but the findings remain inconclusive. We conducted this systematic review and dose-response meta-analysis to investigate the relationship between the DII and CRC and CRA.
Methods: We comprehensively searched the PubMed, Embase, Cochrane Library, and Web of Science databases for cohort and case-control studies reporting the relationship between DII and CRA, or between DII and CRC, as of 15 July 2025.
J Appl Clin Med Phys
September 2025
Department of Radiation Oncology, University of Utah, Salt Lake City, Utah, USA.
Purpose: The development of on-board cone-beam computed tomography (CBCT) has led to improved target localization and evaluation of patient anatomical change throughout the course of radiation therapy. HyperSight, a newly developed on-board CBCT platform by Varian, has been shown to improve image quality and HU fidelity relative to conventional CBCT. The purpose of this study is to benchmark the dose calculation accuracy of Varian's HyperSight cone-beam computed tomography (CBCT) on the Halcyon platform relative to fan-beam CT-based dose calculations and to perform end-to-end testing of HyperSight CBCT-only based treatment planning.
View Article and Find Full Text PDFEur J Med Res
September 2025
Department of Zoology, Faculty of Science, Ain Shams University, Abbassia, Cairo, 11566, Egypt.
Nuclear receptors (NRs) are a superfamily of ligand-activated transcription factors that regulate gene expression in response to metabolic, hormonal, and environmental signals. These receptors play a critical role in metabolic homeostasis, inflammation, immune function, and disease pathogenesis, positioning them as key therapeutic targets. This review explores the mechanistic roles of NRs such as PPARs, FXR, LXR, and thyroid hormone receptors (THRs) in regulating lipid and glucose metabolism, energy expenditure, cardiovascular health, and neurodegeneration.
View Article and Find Full Text PDFDiagn Pathol
September 2025
Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Background: Gastric cancer is one of the most common cancers worldwide, with its prognosis influenced by factors such as tumor clinical stage, histological type, and the patient's overall health. Recent studies highlight the critical role of lymphatic endothelial cells (LECs) in the tumor microenvironment. Perturbations in LEC function in gastric cancer, marked by aberrant activation or damage, disrupt lymphatic fluid dynamics and impede immune cell infiltration, thereby modulating tumor progression and patient prognosis.
View Article and Find Full Text PDF